EGFR and lung cancer: show that in EGFR-mutant-driven lung cancer, disruption of the interaction of PI 3-kinase with normal RAS proteins blocks tumor initiation and promotes regression of existing tumors, highlighting an unexpected vulnerability of EGFR-driven lung cancer.